
Britt K Erickson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/106102/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Molecular profiles of endometrial cancer tumors among Black patients. Gynecologic Oncology, 2022, 166, 108-116.	1.4	11
2	GLS1 is a Protective Factor in Patients with Ovarian Clear Cell Carcinoma and its Expression Does Not Correlate with ARID1A-mutated Tumors. Cancer Research Communications, 2022, 2, 784-794.	1.7	7
3	Sentinel Nodal Metastasis Detection in Endometrial Carcinoma With Microcystic, Elongated, and Fragmented (MELF) Pattern by Cytokeratin Immunostaining. American Journal of Clinical Pathology, 2021, 156, 846-852.	0.7	3
4	Impact of Screening Modality on the Detection of Cervical Adenocarcinoma In Situ and Adenocarcinoma. Journal of Lower Genital Tract Disease, 2021, 25, 267-269.	1.9	2
5	Uterine serous carcinoma: key advances and novel treatment approaches. International Journal of Gynecological Cancer, 2021, 31, 1165-1174.	2.5	40
6	Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies. Current Opinion in Obstetrics and Gynecology, 2020, 32, 57-64.	2.0	27
7	Diagnosis and management of uterine serous carcinoma: current strategies and clinical challenges. Expert Opinion on Orphan Drugs, 2020, 8, 343-355.	0.8	1
8	The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer. Clinical Cancer Research, 2020, 26, 3397-3407.	7.0	45
9	Isolated metastatic pancreatic adenocarcinoma to the uterine cervix: A case report. Gynecologic Oncology Reports, 2019, 29, 61-63.	0.6	3
10	Role of adjuvant radiation or re-excision for early stage vulvar squamous cell carcinoma with positive or close surgical margins. Gynecologic Oncology, 2019, 154, 276-279.	1.4	10
11	Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 138-142.	1.3	5
12	Health Care Provider Adherence to Surgical Guidelines for Risk-Reducing Salpingo-Oophorectomy. Obstetrics and Gynecology, 2019, 134, 520-526.	2.4	9
13	The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction. Gynecologic Oncology, 2019, 152, 127-132.	1.4	28
14	Insulinâ€like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. Cancer Medicine, 2018, 7, 616-625.	2.8	5
15	High Rates of High-Grade Cervical Dysplasia in High-Risk Young Women With Low-Grade Cervical Cytology. Journal of Lower Genital Tract Disease, 2018, 22, 207-211.	1.9	4
16	Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?. Gynecologic Oncology, 2018, 149, 49-52.	1.4	11
17	The Current Landscape of PARP Inhibitors in Ovarian Cancer. Current Obstetrics and Gynecology Reports, 2018, 7, 20-27.	0.8	2
18	Spontaneous Transvaginal Sigmoid Colon Evisceration and Sepsis From Complete Procidentia. Female Pelvic Medicine and Reconstructive Surgery, 2018, 24, e42-e45.	1.1	1

BRITT K ERICKSON

#	Article	IF	CITATIONS
19	An innovative medical school curriculum to address human papillomavirus vaccine hesitancy. Vaccine, 2018, 36, 3830-3835.	3.8	36
20	Müllerian carcinosarcoma arising from atypical pelvic endometriosis. Gynecologic Oncology Reports, 2018, 25, 87-89.	0.6	6
21	Feasibility of Complete Salpingectomy Compared With Standard Postpartum Tubal Ligation at Cesarean Delivery. Obstetrics and Gynecology, 2018, 132, 20-27.	2.4	46
22	The effect of photobiomodulation on chemotherapy-induced peripheral neuropathy: A randomized, sham-controlled clinical trial. Gynecologic Oncology, 2017, 144, 159-166.	1.4	30
23	Enhanced Recovery Program and Length of Stay After Laparotomy on a Gynecologic Oncology Service. Obstetrics and Gynecology, 2017, 129, 355-362.	2.4	47
24	Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma – A multi-institutional cohort. Gynecologic Oncology, 2017, 144, 274-278.	1.4	27
25	See-and-Treat for High-Grade Cytology: Do Young Women Have Different Rates of High-Grade Histology?. Journal of Lower Genital Tract Disease, 2016, 20, 243-246.	1.9	10
26	Trends in Colposcopy Volume: Where Do We Go From Here?. Journal of Lower Genital Tract Disease, 2016, 20, 292-295.	1.9	9
27	Cervical cancer screening: evidence behind the guidelines. American Journal of Obstetrics and Gynecology, 2016, 214, 438-443.	1.3	73
28	Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer. Oncotarget, 2014, 5, 8750-8764.	1.8	107
29	Detection of Somatic TP53 Mutations in Tampons of Patients With High-Grade Serous Ovarian Cancer. Obstetrics and Gynecology, 2014, 124, 881-885.	2.4	44
30	Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center. Gynecologic Oncology, 2014, 133, 142-146.	1.4	50
31	Diabetes mellitus and ovarian cancer: More complex than just increasing risk. Gynecologic Oncology, 2014, 135, 273-277.	1.4	41
32	Black race independently predicts worse survival in uterine carcinosarcoma. Gynecologic Oncology, 2014, 133, 238-241.	1.4	26
33	Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma. Gynecologic Oncology, 2014, 133, 234-237.	1.4	17
34	Update on Vaccination Clinical Trials for HPV-Related Disease. Clinical Therapeutics, 2014, 36, 8-16.	2.5	26
35	Cost-effectiveness Analysis of Sentinel Lymph Node Biopsy in the Treatment of Early-Stage Vulvar Cancer. International Journal of Gynecological Cancer, 2014, 24, 1480-1485.	2.5	26
36	Pre-operative imaging with CA125 is a poor predictor for granulosa cell tumors. Gynecologic Oncology, 2013, 131, 59-62.	1.4	18

BRITT K ERICKSON

#	Article	IF	CITATIONS
37	Human papillomavirus: what every provider should know. American Journal of Obstetrics and Gynecology, 2013, 208, 169-175.	1.3	48
38	The role of the fallopian tube in the origin of ovarian cancer. American Journal of Obstetrics and Gynecology, 2013, 209, 409-414.	1.3	238
39	Reply. American Journal of Obstetrics and Gynecology, 2013, 209, 396.	1.3	0
40	Low yield of residual vulvar carcinoma and dysplasia upon re-excision for close or positive margins. Gynecologic Oncology, 2013, 129, 528-532.	1.4	18
41	Screening Behaviors and Cultural Barriers in Women with Newly Diagnosed Cervical Cancer. Journal of Lower Genital Tract Disease, 2013, 17, 425-429.	1.9	5
42	Vaginal Cancer. Journal of Lower Genital Tract Disease, 2013, 17, 409-413.	1.9	16
43	Isolated Symptomatic Cardiac Recurrence of Endometrial Stromal Sarcoma Treated Successfully with Surgical Resection. Journal of Gynecologic Surgery, 2012, 28, 140-142.	0.1	0
44	Survey of Robotic Surgery Credentialing Requirements for Physicians Completing OB/GYN Residency. Journal of Minimally Invasive Gynecology, 2012, 19, 589-592.	0.6	14
45	New insights into cervical cancer screening. Journal of Gynecologic Oncology, 2012, 23, 282.	2.2	47
46	Referral Patterns and Incidence of Cervical Intraepithelial Neoplasia in Adolescent and Pregnant Patients. Journal of Lower Genital Tract Disease, 2011, 15, 124-127.	1.9	4
47	Invasive Cervical Cancer and Screening. Journal of Lower Genital Tract Disease, 2011, 15, 110-113.	1.9	41
48	Changes in incidence and indications of tonsillectomy and adenotonsillectomy, 1970â€2005. Otolaryngology - Head and Neck Surgery, 2009, 140, 894-901.	1.9	179